Corporate Member Update: Merck-WELIREG™ (belzutifan)
Corporate Member Update: Merck-WELIREG™ (belzutifan)
WELIREG™ (belzutifan)
September, 2021
Merck Product Launch
Merck would like to inform you that WELIREG™ (belzutifan) 40-mg tablets has received FDA approval. WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
To read the full press release, please click here!